Online ISSN: 2515-8260

Keywords : Cardiovascular


Serum Renalase and its Relation to Left Ventricular Hypertrophy in Patients on Hemodialysis

Samar Gomaa Gamal, Adel Abd ElMohsen Ghorab, Islam Ali Elsayed, Said M Al-Barshomy,Nader Mohammad Mustafa

European Journal of Molecular & Clinical Medicine, 2021, Volume 8, Issue 4, Pages 857-871

Background: Renalase is a blood-secreted protein produced only by the kidney; its
blood level approximately 3–5 μg/ml. The Left ventricular hypertrophy (LVH) is
defined by an augmented left ventricular mass that may be measured via
echocardiography or magnetic resonance imaging (MRI). The aim of the present
study was to study whether Renalase is a marker or has a potential role in
developing myocardial hypertrophy in CKD patients under hemodialysis (HD)
treatment.
Patients and methods: To achieve this target, 90 patients on maintenance HD were
incorporated in the present study.
Results: The mean renalase levels were 61.7±67.5 ng/mL in HD patients. The cutoff
value of Renalase was >57.9 ng/ml with a sensitivity of 92.3% and a Specificity of
84.0%. The mean LVMI of the studied dialysis patients was 138 g/m2. The majority
of cases were severely abnormal (60%). There was a statistically significant
difference between the age groups and the LVMI among dialysis patients. The level
of Renalase was significantly increased with the moderately and severely abnormal
LVMI among dialysis patients. The present study disclosed statistically significant
relations between the duration of dialysis and Renalase, HDL, CRP, and LVMI.
There were significant relations between the serum renalase and s. creat, bl. Urea,
Ph, LVMI and dialysis vintage. Also, there were significant positive relations
between LVMI and Hb, CRP, and dialysis vintage.
Conclusion: Renalase could be a novel predictive biomarker in the assessment of
LVH, which is closely associated with the increased risk of death in HD patients.

Assessment of cardiovascular manifestations of hyperthyroid disorder patients

Dr.Mayank Panwar,Dr.Akanksha,Dr. Bijoy Jyoti Saikia, Dr.Peddi Shreya

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 11, Pages 9414-9417

Background: Hyperthyroidism is defined as excess concentration of thyroid hormones
in the body due to either increased synthesis of the thyroid hormone, increased release
of preformed thyroid hormones, or from endogenous or exogenous extrathyroidal
sources. The present study was conducted to assess cardiovascular manifestations of
hyperthyroid disorder patients.
Materials & Methods: 104 patients of hyperthyroidism of both gendersunderwent
clinical evaluation, basic laboratory tests like CBC, RFT, LFT and ECG and 2D ECHO
were performed in these patients to evaluate the presence of any cardiac manifestations.
Results: There were 34 males and 70 females. Age group upto 40 years had 20, 41-60
years had 34 and >61 years had 50 patients. Common symptoms were pallor in 90,
edema in 86, moist skin in 74 and eye signs in 53. Cardiovascular symptoms recorded
were chest pain in 82, palpitations in 95 and breathlessness in 60. Among 104 patients,
ECG changes were seen in 42 patients. Out of this, sinus tachycardia was seen in 65%,
AF in 10%, ST T changes in 6%, RVH in 7%, LVH in 11% and RBBB in 5%. The
difference was significant (P< 0.05).
Conclusion: Cardiovascular manifestations are quite common in hyperthyroid patients.

An Observational Study Of Cardiovascular Outcome In Patients Undergoing Primary Pci With Indian Manufactured Des

Dr. Pragathi Gurram; Dr. Suresh Yerra

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 7, Pages 6795-6811

Background: Raising cardiovascular diseases and its associated comorbidity, health risks and consequences carry a massive health care system and economic burden on the society. Aim: To compare the different Indian manufactured drug eluting stents (DES) in patients undergoing primary percutaneous coronary intervention (PCI) with primary objective of major adverse cardiac and cerebrovascular events (MACCE). Study design: Observational, retrospective, and prospective study. Methodology: Study conducted at Sunshine Heart Institute from Jan 2016 to April 2018 in all the patients who have undergone primary PCI with Indian manufactured DES. The baseline clinical, procedural, in-hospital data and follow-up data was taken at 01, 03, 06 and 12 months, till end of study period at regular intervals, after the index procedure. Results: 163 patients were considered for the data analysis in 3 groups i.e. Premier (51), Tetrilimus (47) & YCF (65). Conclusion: All the three study groups have shown similar primary and secondary outcomes. However, further studies are required on large scale for accurate assessment and evaluation.